Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 48: 2248-2251, 2002;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (9)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Borofsky, N. D.
Right arrow Articles by Orentreich, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Borofsky, N. D.
Right arrow Articles by Orentreich, N.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2002;48:2248-2251.)
© 2002 American Association for Clinical Chemistry, Inc.

Technical Briefs

Utility of Insulin-like Growth Factor-1 as a Biomarker in Epidemiologic Studies

Nancy D. Borofskya, Joseph H. Vogelman, Rozlyn A. Krajcik and Norman Orentreich

1 Orentreich Foundation for the Advancement of Science, Inc., 855 Route 301, Cold Spring-on-Hudson, NY 10516

aauthor for correspondence: fax 845-265-4210, e-mail ofas1@juno.com

The first 300 words of the full text of this article appear below.

Recent studies have correlated high serum insulin-like growth factor-1 (IGF-1) with increased risk of several common cancers, primarily prostate, breast, colorectum, and lung (1)(2)(3); low concentrations of circulating IGF-1 have been associated with osteoporosis (4), impaired cognitive function (5), and heart disease (6). IGF-1 screening may help prevent chronic disease by identifying high-risk individuals (7)(8). Although normal adult IGF-1 concentrations relative to age and sex have been widely reported, based on cross-sectional data (9)(10)(11)(12)(13)(14), there have been few longitudinal studies. Most studies measuring multiple samples followed only a few individuals over short periods (15)(16)(17)(18)(19). Knowing the degree of individual variation over longer time periods would be useful (20).

Staff volunteers gave informed consent for the study. Blood was drawn monthly between 0800 and 1000 in the morning from 26 apparently healthy adults, and medications and time of last meal were recorded. Within 1 h of collection, samples were centrifuged, and serum was stored at -20 °C until analysis, which was within 1 month of collection. Serum IGF-1 was measured in 13 men (starting ages, 24–77 years; median, 49 years) and 13 women (starting ages, 23–56 years; median, 41 years). The total number of samples from each individual varied from 13 to 56 (mean, 31), and they were collected over 1.2–6 years (mean, 4.5 years). Use of previously collected serum stored at -40 °C extended the time period followed for two male volunteers to 16 years. In addition, multiple aliquots from three male volunteers (ages, 26, 44, and 75 years) used for assessing interassay variability were stored at -20 °C for . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
S. H. Siahpush, T. L. Vaughan, J. N. Lampe, R. Freeman, S. Lewis, R. D. Odze, P. L. Blount, K. Ayub, P. S. Rabinovitch, B. J. Reid, et al.
Longitudinal Study of Insulin-like Growth Factor, Insulin-like Growth Factor Binding Protein-3, and their Polymorphisms: Risk of Neoplastic Progression in Barrett's Esophagus
Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2387 - 2395.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
L. Baglietto, D. R. English, J. L. Hopper, H. A. Morris, W. D. Tilley, and G. G. Giles
Circulating Insulin-Like Growth Factor-I and Binding Protein-3 and the Risk of Breast Cancer
Cancer Epidemiol. Biomarkers Prev., April 1, 2007; 16(4): 763 - 768.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
I. dos Santos Silva, N. Johnson, B. De Stavola, G. Torres-Mejia, O. Fletcher, D. S. Allen, N. E. Allen, T. J. Key, I. S. Fentiman, J. M.P. Holly, et al.
The insulin-like growth factor system and mammographic features in premenopausal and postmenopausal women.
Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 449 - 455.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Association for Clinical Chemistry.